Optimització en l’obtenció d’Hupertacrina-Tacrina pel tractament de la malaltia d’Alzheimer


Comallonga Albareda, Cèlia


Alzheimer's disease (AD) is one of the most studied diseases worldwide so that, despite having been described for the first time at the beginning of the 20th century and currently affects more than 30 million people around the world, although he is not careful. However, drugs have been found that slow the progress of this disease, mainly inhibiting acetylcholinesterase (AChE) and butyrylcholinesterase (crop). In previous studies developed in the Pharmaceutical Chemistry Group, a new molecule derived from Tacrine was investigated that could present greater effectiveness and less toxicity than this, in addition to presenting a dual inhibition of the two esterases, thus becoming a potential and innovative drug for the treatment of AD.
This work exposes the optimization of the process for obtaining this multi target compound, achieving an improvement in performance in most synthetic stages, and obtaining a sufficient quantity to carry out biological activity studies.



Puig de la Bellacasa Cazorla, Raimon
Borrell Bilbao, José Ignacio  


IQS SE - Undergraduate Program in Pharmacy